this article describes the acelrx's fiyrtg quarter and Tetraphase acquisition conference call. acelrx is a new institution with two innovative products, xava, and dsuvia. this is an important transaction that provides strategic benefits to both companies. in fact, we entered into a co-promotion agreement which allows us to quickly realize some key benefits from the transaction. in addition, we announced our previously previewed third quarter financial results and provided an update on our commercial launch of dsuvia. in addition, we provided an update on our financial results and provided an update on our commercial release of dsuvia.